|Table of Contents|

Research progress of CRISPR/Cas9 technology in the diagnosis and treatment of ovarian cancer and related mechanisms of cancer metastasis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 03
Page:
587-590
Research Field:
Publishing date:

Info

Title:
Research progress of CRISPR/Cas9 technology in the diagnosis and treatment of ovarian cancer and related mechanisms of cancer metastasis
Author(s):
DAI Guiming; JIANG Hui
The Fifth Affiliated Hospital of Guangzhou Medical University,Guangdong Guangzhou 510700,China.
Keywords:
CRISPR/Cas9; gene editor; ovarian cancer; distant metastasis
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.03.040
Abstract:
Ovarian cancer is one of the most common gynecological malignancies,and its main treatment means are surgery,radiotherapy and chemotherapy as adjuvant therapy for ovarian cancer.Advanced ovarian cancer is especially prone to distant metastasis,so the diagnosis and treatment of metastatic ovarian cancer is also the focus of our clinical treatment of ovarian cancer.The CRISPR/Cas9 system mediated genome editing system can obtain gene knockout mutants faster than the traditional gene editing technology,which is expected to use CRISPR/Cas9 to analyze the pathogenesis and metastasis of ovarian cancer,thus accelerating the research of ovarian cancer.This article briefly introduces CRISPR/Cas9 technology and reviews the application status and prospects of CRISPR/Cas9 technology in the treatment of ovarian cancer and its occurrence,development and metastasis in advanced stage in recent years.

References:

［1］STEWART C,RALYEA C,LOCKWOOD S.Ovarian cancer:An integrated review［J］.Semin Oncol Nurs,2019,35(2):151-156.
［2］ERNST L.Ovarian cancer development and metastasis［J］.The American Journal of Pathology,2010,177(3):1053-1064.
［3］MORIO F,LOMBARDI L,BUTLER G.The CRISPR toolbox in medical mycology:State of the art and perspectives［J］.PLoS Pathog,2020,16(1):e1008201.
［4］LEONOVA EI,GAINETDINOV RR.CRISPR/Cas9 technology in translational biomedicine［J］.Cell Physiol Biochem,2020,54(3):354-370.
［5］LI J,QIN X,SHI J,et al.A systematic CRISPR screen reveals an IL-20/IL20RA-mediated immune crosstalk to prevent the ovarian cancer metastasis［J］.Elife,2021,10:e66222.
［6］GASIUNAS G,BARRANGOU R,HORVATH P,et al.Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria［J］.Proc Natl Acad Sci USA,2012,109(39):E2579-2586.
［7］TYAGI S,KUMAR R,DAS A,et al.CRISPR-Cas9 system:A genome-editing tool with endless possibilities［J］.J Biotechnol,2020,319:36-53.
［8］CONG L,RAN FA,COX D,et al.Multiplex genome engineering using CRISPR/Cas systems［J］.Science,2013,339(6121):819-823.
［9］OPHINNI Y，INOUE M，KOTAKI T，et al． CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures［J］.Sci Rep,2018,8(1):7784.
［10］KHADEMPAR S,FAMILGHADAKCHI S,MOTLAGH RA,et al.CRISPR-Cas9 in genome editing:Its function and medical applications［J］.J Cell Physiol,2019,234(5):5751-5761.
［11］LYU Q，YUAN L，DENG J，et al．Efficient generation of myostatin gene mutated rabbit by CRISPR/Cas9［J］.Sci Rep,2016,6:25029.
［12］BARMAN A,DEB B,CHAKRABOETY S.A glance at genome editing with CRISPR-Cas9 technology［J］.Curr Genet,2020,66(3):447-462.
［13］CHEN M,MAO A,XU M,et al.CRISPR-Cas9 for cancer therapy:Opportunities and challenges［J］.Cancer Lett,2019,447:48-55.
［14］BANAN M.Recent advances in CRISPR/Cas9-mediated knock-ins in mammalian cells［J］.J Biotechnol,2020,308:1-9.
［15］VAN ZA,WARDHANI TAK,SEIFI KM.CRISPR/Cas9-mediated mutagenesis of four putative symbiosis genes of the tropical tree parasponia andersonii reveals novel phenotypes［J］.Front Plant Sci,2018,9:284.
［16］LEMOS BR,KAPLAN AC,BAE JE,et al.CRISPR/Cas9 cleavages in budding yeast reveal templated insertions and strand-specific insertion/deletion profiles［J］.Proc Natl Acad Sci USA,2018,115(9):E2040-E2047.
［17］雷婷,肖斌,何咏茵,等.CRISPR/Cas9 文库筛选技术的发展及在肿瘤研究中的应用［J］.南方医科大学学报,2019,39(11):1381-1386. LEI T,XIAO B,HE YY,et al.Development and applications of CRISPR/Cas9 library screening technology in cancer research［J］.Journal of Southern Medical University,2019,39(11):1381-1386.
［18］程得洛.CRISPR/Cas9基因编辑技术及其在肿瘤治疗方面的研究进展［J］.系统医学,2020,5(20):195-198. CHENG DL.CRISPR/Cas9 gene editing technology and its research progress in tumor therapy［J］.Systems Medicine,2020,5(20):195-198.
［19］YEUNG TL,LEUNG CS,YIP KP,et al.Cellular and molecular processes in ovarian cancer metastasis.A review in the theme:Cell and molecular processes in cancer metastasis［J］.Am J Physiol Cell Physiol,2015,309(7):C444-456.
［20］ROSENBLUM D,GUTKIN A,KEDMI R,et al.CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy［J］.Sci Adv,2020,6(47):eabc9450.
［21］KALHOR R,MALI P,CHURCH GM.Rapidly evolving homing CRISPR barcodes［J］.Nat Methods,2017,14(2):195-200.
［22］EBRAHIMI V,HASHEMI A.Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions:A review［J］.Gene,2020,753:144813.
［23］CAMBELL LA,COKE LM,RICHIE CT,et al.Gesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex for inactivating the HIV provirus［J］.Mol Ther,2019,27(1):151-163.
［24］LU T,ZHANG L,ZHU W,et al.CRISPR/Cas9-mediated OC-2 editing inhibits the tumor growth and angiogenesis of ovarian cancer［J］.Frontiers in Oncology,2020,10:1529.
［25］LI J,MA J,MENG G,et al.BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells［J］.Stem Cell Res,2016,17(2):212-221.
［26］SU S,HU B,SU J,et al.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients［J］.Sci Rep,2016,6:20070.
［27］张骞,李力.CRISPR/Cas9基因编辑技术在妇科恶性肿瘤研究及治疗中应用的进展［J］.中华妇产科杂志,2018,53(01):65-70. ZHANG Q,LI L.The advances in the application of CRISPR/Cas9 gene editing technology in the study and treatment of gynecological malignancies［J］.Chin J Obstet Gynecol,2018,53(01):65-70.
［28］张伊黎,李力.CRISPR/Cas9技术在卵巢癌多药耐药诊治中的应用［J］.现代妇产科进展,2020,29(09):706-709. ZHANG YL,LI L.The application of CRISPR/Cas9 in the diagnosis and treatment of multidrug resistance in ovarian cancer［J］.Prog Obstet Gynecol,2020,29(09):706-709.
［29］ELIIES A,RIVIERE S,POUGET N,et al.The role of neoadjuvant chemotherapy in ovarian cancer［J］.Expert Rev Anticancer Ther,2018,18(6):555-566.
［30］STOVER EH,BACO MB,COHEN O,et al.Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer［J］.Mol Cancer Res,2019,17(11):2281-2293.
［31］KOYANGI T,SAGA Y,TAKAHASHI Y,et al.Knockout of vasohibin-2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer［J］.Cancer Med,2021,10(8):2732-2739.
［32］COURTNEY DG,MOORE JE,ATKINSON SD,et al.CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting［J］.Gene Ther,2016,23(1):108-112.
［33］MAKVANDI M,PANTEL A,SCHWARTZ L,et al.A PET imaging agent for evaluating PARP-1 expression in ovarian cancer［J］.J Clin Invest,2018,128(5):2116-2126.

Memo

Memo:
中国医药学研究生在线教育教学研究课题（编号：A-YXC20200202-07）;广东省研究生教育创新计划项目（编号：2019JGXM85）
Last Update: 1900-01-01